Specialty R&D


Our innovations meet important medical needs
Our Specialty Pharma business delivers innovative medicines focused on meeting important medical needs across therapeutic categories, including central nervous system disorders (Parkinson’s Disease, Spasticity, Migraine), endocrinology (Hypothyroidism), and other therapeutic areas.
We are focused on the continued growth and expansion of our product portfolio through internal development as well as through acquisitions and late-stage and next-generation product partnership opportunities.
Clinical Activities
Product
Indication
Estimated Launch
IPX203
Parkinson’s Disease
Q3’23
DHE Autoinjector
Migraine and Cluster Headache
2025
K-127
Myasthenia Gravis*
2024
K-128
Movement Disorders
2025-2026
K-114
Hypothyroidism
2026-2027
K-130
Neurogenic Orthostatic, Hypotension
2027
*Orphan Disease
**As of March 2023
© 2023 Amneal Pharmaceuticals LLC. All rights reserved.